Your session is about to expire
← Back to Search
Other
Effects of Augmented Renal Clearance on Pharmacokinetic and Pharmacodynamic Properties of Levetiracetam in Subarachnoid Hemorrhage
N/A
Waitlist Available
Led By Edward T Van Matre, PharmD
Research Sponsored by University of Colorado, Denver
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0-20 days
Awards & highlights
No Placebo-Only Group
Summary
This study evaluates the pharmacokinetic profile of levetiracetam in critically ill patients who have suffered a subarachnoid hemorrhage. The patients will be evaluated for development of augmented renal clearance and the effects and duration of effects this may have on levetiracetam clearance.
Eligible Conditions
- Subarachnoid Hemorrhage
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 0-20 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0-20 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in systemic levetiracetam clearance over time
Secondary study objectives
Change in urinary clearance of levetiracetam and creatinine
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Subarachnoid HemorrhageExperimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
University of Colorado, DenverLead Sponsor
1,810 Previous Clinical Trials
2,920,085 Total Patients Enrolled
1 Trials studying Subarachnoid Hemorrhage
30 Patients Enrolled for Subarachnoid Hemorrhage
Edward T Van Matre, PharmDPrincipal InvestigatorUniversity of Colorado School of Pharmacy